Immunotherapy regimens targeting the PD-1 or EGFR pathways have variable response rates52,53, demonstrating the importance of identifying novel molecular pathways associated with HNSCC carcinogenesis. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.